Cerebral Resuscitation

1. Pathophysiology: Ischemia-Reperfusion Injury

Cellular Level

• Mitochondrial dysfunction: cytochrome c release, disruption of oxidative phosphorylation, activation of programmed cell death pathways
• Reactive oxygen species (ROS): surge of superoxide and hydrogen peroxide overwhelms catalase and superoxide dismutase; lipid peroxidation and DNA damage
• Excitotoxicity: excess glutamate release leads to calcium influx and neuronal death

Humoral / Systemic Level

• Reperfusion triggers broad immune activation: IL-6, TNF-alpha elevation, aberrant neutrophil and platelet activation
• This "sepsis-like syndrome" (described by Adrie et al.) causes additional ROS production and vascular endothelial injury
• Vascular leak, loss of peripheral vascular resistance, intravascular volume depletion, and hypotension

Organ-Level Consequences

• Cerebral edema and raised intracranial pressure (ICP) - can cause herniation and death within the first 72 hours
• Myocardial stunning: global hypokinesis and reduced ejection fraction (usually transient, resolves over days)
• Post-resuscitation infection from bacterial translocation due to loss of intestinal integrity
• Adrenal insufficiency from ischemic adrenal injury

2. Priorities After ROSC

A. Restore and Maintain Cerebral Perfusion Pressure (CPP)

• Use IV fluids and vasopressors (norepinephrine preferred) to achieve MAP targets
• Avoid inducing hypertension due to risk of worsening vasogenic edema and disrupting the blood-brain barrier
• Loss of autoregulation means CBF changes of ~2% per 1 mm Hg PaCO2 change - hyperventilation acutely lowers ICP but causes cerebrovascular constriction and worsens ischemia if sustained

B. Oxygenation and Ventilation

• Target normoxia - both hypoxia and hyperoxia worsen outcomes
• Target normocarbia (PaCO2 35-45 mm Hg)
• Hyperventilation (PaCO2 <30 mm Hg) reduces CBF by 2% per 1 mm Hg drop - appropriate only as a bridge to abort acute herniation, not as sustained therapy
• Titrated sedation (propofol preferred - reduces cerebral metabolic rate, clears rapidly for neurological assessment) or dexmedetomidine
• Avoid ventilator dyssynchrony and coughing (ICP spikes)

3. Targeted Temperature Management (TTM)

Mechanism of Benefit

• Cerebral metabolic rate (8-13% per °C)
• Glutamate release and excitotoxicity
• Free radical production
• Cytoskeletal breakdown and blood-brain barrier disruption
• Inflammatory cascade activation

Evidence

Target Temperature

• 32-36°C is the accepted range; most protocols target 33°C or 36°C
• Do not allow temperature to fall below 32°C (risk of arrhythmias)
• Maintain for 24 hours, then rewarm over 12-24 hours (rapid rewarming causes hypotension and electrolyte shifts)

Inclusion Criteria

• Post-ROSC with GCS motor score <6
• No other explanation for coma
• No DNR/DNI status
• Adult (age >17 years)

Exclusion Criteria

• Awake/alert after arrest
• Traumatic or hemorrhagic arrest
• Pre-arrest coma or vegetative state
• Pregnancy (relative)

Practical Points

• Start cooling as early as possible in the ED; continue in the ICU/cath lab
• Use surface cooling devices or endovascular catheters with temperature probes (servo-control)
• Check electrolytes every 4 hours during cooling (hypokalemia from cold-mediated diuresis; hyperkalemia during rewarming)
• Maintain MAP >60 mm Hg throughout
• Prehospital cold saline infusion is NOT recommended - trials showed no benefit and possibly increased re-arrest rate

Complications

Special Populations

• Pediatric: No definitive benefit in children (unlike neonatal HIE where TTM is well-established). Avoid fever at minimum.
• Pregnancy: Multiple case reports of good outcomes; not an absolute exclusion.
• Cath lab: TTM can be safely continued during cardiac catheterization.

4. ICP Management

1. Head positioning: 30-degree head elevation; avoid flat position
2. Analgesia and sedation: Fentanyl 25-50 mcg IV prn; propofol infusion (reduces CMRO2 and CBF); dexmedetomidine as alternative
3. Normoventilation (PaCO2 35-45); brief hyperventilation (PaCO2 30-35) only for acute herniation as bridge
4. Osmolar therapy: Mannitol (0.25-1 g/kg IV) or hypertonic saline (3% NaCl) - both draw water from brain
5. CSF drainage via ventriculostomy if present
6. Refractory ICP: Pentobarbital infusion (10 mg/kg load over 30 min, then 1-4 mg/kg/h) titrated to burst suppression on EEG; often requires vasopressors
7. Surgical: Decompressive craniectomy for refractory cases (shown to reduce 6-month mortality by 22% in severe TBI, though without improvement in disability-free survival)

5. Neuroprognostication

6. Other Post-Resuscitation Care

• Early coronary angiography/PCI: Most appropriate for VF/VT arrest with suspected coronary occlusion; myocardial ischemia is the most common cause of SCA
• Glycemic control: Avoid hyperglycemia and hypoglycemia
• Seizure treatment: Treat clinical and electrographic seizures aggressively (benzodiazepines, levetiracetam, valproate); consider prophylaxis in selected cases
• Hemodynamic support: Echo to assess myocardial stunning; vasopressors/inotropes as needed; consider intra-aortic balloon pump or ECMO in refractory cardiogenic shock
• Fever avoidance: Hyperthermia (>37.6°C) after arrest dramatically worsens outcome; aggressive fever control even if full hypothermia is not initiated

Recent Evidence (2025-2026)